Patients with Parkinson's disease (PD) receiving L-3,4-dihydroxyphenylalanine (L-DOPA, the gold-standard treatment for this disease) frequently develop abnormal involuntary movements, termed L-DOPA-induced dyskinesias (LID). Glutamate overactivity is well documented in PD and LID. An approach to manage LID is to add to L-DOPA specific agents to reduce dyskinesias such as metabotropic glutamate ...

A new TLC separation and quantitation method for L-tyrosine and L-Dopa mixtures was developed. The minimum tyrosine and Dopa quantities which can be measured by this technique are 0.7 and 1.5 μg respectively. The method may be used to measure the kinetic parameters of polyphenoloxidase as well as to trace the enzyme catalyzed conversion of L-tyrosine into L-Dopa. For a set of 20 measurements th...

UNLABELLED Infiltrative astrocytomas (IAs) represent a group of astrocytic gliomas ranging from low-grade to highly malignant, characterized by diffuse invasion of the brain parenchyma. When compared with their adult counterpart, pediatric IAs may be considered biologically distinct entities; nevertheless, similarly to those in adults they represent a complex oncologic challenge. The aim of thi...

In this study, microbial production of L-Dopa and Dopamine which is an important substrance for the treatment Parkinson's disease were investigated by using Citrobacter freundii (NRRL B-2643). The effects carbon source (sucrose) and, salt concentrations (NaCl, CaCl2), initial pH, temperature, inoculum level shaking speed on dopamine investigated. amounts extracellular L-dopa determined HPLC. Ma...

Acute renal hypertension is produced by the injection of the amino acid dopa (l-dihydroxyphenylalanine) into the partially or completely ischemic kidney of the cat. Evidence is presented suggesting that the rise in blood pressure following the injection of dopa is caused by its conversion into hydroxytyramine, a pressor amine. Kidneys with normal blood flow fail to transform dopa into a pressor...

BACKGROUND Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD. METHODS Phase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50 mg once-daily (n = 38) or placebo (n = 20) for 7 to 9 days. RE...

Synthetic mesoporous alumina and silica minerals with uniform pore geometries, and their nonporous analogues, were used to test the role of mineral mesopores (2-50 nm diameter) in protecting organic matter from enzymatic degradation in soils and sediments. Dihydroxyphenylalanine (L-DOPA), a model humic compound, was irreversibly sorbed to both mineral types. The surface area-normalized adsorpti...

Voluntary movement difficulties in Parkinson's disease are initially relieved by l-DOPA therapy, but with disease progression, the repeated l-DOPA treatments can produce debilitating motor abnormalities known as l-DOPA-induced dyskinesias. We show here that 2 striatum-enriched regulators of the Ras/Rap/ERK MAP kinase signal transduction cascade, matrix-enriched CalDAG-GEFI and striosome-enriche...

Dyskinesia is a major side effect of chronic levodopa (L-DOPA) administration, the reference treatment for Parkinson's disease (PD). High-frequency stimulation of the subthalamic nucleus (STN-HFS) alleviates parkinsonian motor symptoms and indirectly improves dyskinesia by decreasing L-DOPA requirement. However, inadequate stimulation can also trigger dyskinetic movements in PD patients and ani...

S t u d y s e l e c t i o n a n d a s s e s s m e n t Studies were selected if they were randomized controlled trials (RCTs) of pharmacologic (dopamine agonists [DAs] plus L-dopa, selegiline plus L-dopa, or catechol O-methyl transferase [COMT] inhibitors plus L-dopa vs L-dopa alone), psychiatric (piracetam or citalopram vs placebo), surgical (pallidotomy, deep brain stimulation [DBS], and fetal...